Investor Relations

IR Home

Effect of Reclassification

Recent Newsmore >
08/15/16
Clinical Studies Demonstrate ConforMIS iTotal CR Customized Knee Implants Provide Superior Outcomes and Potential for Economic Savings
New clinical study demonstrates potential for ConforMIS iTotal CR customized knee implants to contribute cost savings across episode of care BEDFORD, Mass., Aug. 15, 2016 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that develops, manufactures and sells joint replacement implants that are customized to fit each patient's unique anatomy, announced today the results from two clinical studies presented at the ICJR Pan Pacific Orthopaedic Congress, August 10 – 1... 
08/08/16
ConforMIS Reports Second Quarter 2016 Financial Results and Updates Fiscal Year 2016 Revenue Guidance
BEDFORD, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, announced today financial results for the second quarter ended June 30, 2016. Q2 Summary: Total revenue of $19.3 million, up 1% year-over-year on a reported basis and no change year-over-year o... 
Upcoming Eventsmore >
01/09/17 through 01/11/17
ConforMIS, Inc. at the J.P. Morgan Conference
remind me days before the event

Enter your e-mail address 
IR Contact
Oksana Bradley
Investor Relations
Phone: (781) 374-5598
E-mail: ir@conformis.com

Media Contacts
Bill Berry
Berry & Company Public Relations
Phone: (212) 253-8881
E-mail: Bberry@berrypr.com

Lynn Granito
Berry & Company Public Relations
Phone: (212) 253-8881
E-mail: Lgranito@berrypr.com
Featured Reports
There are currently no items available.
Data provided by Nasdaq. Minimum 15 minutes delayed.